Literature DB >> 2471088

Kinetics of drug binding to human serum albumin: allosteric and competitive inhibition at the benzodiazepine binding site by free fatty acids of various chain lengths.

G Menke1, W Wörner, W Kratzer, N Rietbrock.   

Abstract

The inhibition of dansylsarcosine (DS) binding at the benzodiazepine binding site of human serum albumin has been studied in the presence of saturated and unsaturated free fatty acids (FFA) of various chain lengths (C6-C20, C18:1, C18:2). In order to determine the mechanism of displacement, velocity constants for association (k2) and dissociation (k-2) and binding constants (KA and KA') have been measured using the stopped-flow method. The inhibitory effect of FFA on DS binding kinetics at site II is dependent of their structure. With increasing amounts of FFA the association velocity constant of DS binding decreases from 520 s-1 (fatty acid free albumin) by a factor of 3-10 and affinity decreases according to FFA chain length. Inhibition is strongest in the presence of caprylic, capric and lauric acid (C8-C12) i.e. with more than one mole FFA per mole albumin, DS association could no longer be measured. Short chain caproic and the long chain FFA C14-C20 showed only a less inhibitory effect since in the presence of a twofold excess k2 ranged between 100 and 200 s-1. Dissociation velocity of DS from the benzodiazepine binding site could be measured in relationship to FFA chain length using ibuprofene, another drug binding at site II. Dissociation velocity constants k-2 remained constant up to 2 moles FFA per mole albumin (k-2 = 16-18 s-1). A rise in k-2 to 70 s(-1) was seen, however, when 2-4 moles capric, lauric, myristic and palmitic (C10-C16) acid were bound, whereas no change was observed when increasing concentrations of caproic, caprylic, stearic and arachic acid.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2471088     DOI: 10.1007/bf00165124

Source DB:  PubMed          Journal:  Naunyn Schmiedebergs Arch Pharmacol        ISSN: 0028-1298            Impact factor:   3.000


  8 in total

1.  The characterization of two specific drug binding sites on human serum albumin.

Authors:  G Sudlow; D J Birkett; D N Wade
Journal:  Mol Pharmacol       Date:  1975-11       Impact factor: 4.436

2.  Age-dependence and free fatty acid modulation of binding kinetics at the benzodiazepine binding site of serum albumin in neonates and adults determined using fast reaction methods.

Authors:  G Menke; P Pfister; S Sauerwein; I Rietbrock; B G Woodcock; N Rietbrock
Journal:  Br J Clin Pharmacol       Date:  1987-04       Impact factor: 4.335

3.  Human serum albumin. Spectroscopic studies of binding and proximity relationships for fatty acids and bilirubin.

Authors:  C B Berde; B S Hudson; R D Simoni; L A Sklar
Journal:  J Biol Chem       Date:  1979-01-25       Impact factor: 5.157

4.  Influence of free fatty acid concentration on drug binding to plasma albumin.

Authors:  A A Spector; E C Santos; J D Ashbrook; J E Fletcher
Journal:  Ann N Y Acad Sci       Date:  1973-11-26       Impact factor: 5.691

Review 5.  Molecular aspects of ligand binding to serum albumin.

Authors:  U Kragh-Hansen
Journal:  Pharmacol Rev       Date:  1981-03       Impact factor: 25.468

6.  Influence of palmitate and oleate on the binding of warfarin to human serum albumin: stopped-flow studies.

Authors:  N Rietbrock; G Menke; G Reuter; A Lassmann; R Schmeidl
Journal:  J Clin Chem Clin Biochem       Date:  1985-11

7.  Stopped-flow studies on drug-protein binding. 1. Kinetics of warfarin binding to human serum albumin.

Authors:  N Rietbrock; A Lassmann
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1980-09       Impact factor: 3.000

8.  Structural requirements for drug binding to site II on human serum albumin.

Authors:  S Wanwimolruk; D J Birkett; P M Brooks
Journal:  Mol Pharmacol       Date:  1983-11       Impact factor: 4.436

  8 in total
  1 in total

1.  Drug-protein binding kinetics in patients with type I diabetes.

Authors:  W Wörner; A Preissner; N Rietbrock
Journal:  Eur J Clin Pharmacol       Date:  1992       Impact factor: 2.953

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.